Cochrane Abstracts
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Alemtuzumab Versus Interferon Beta 1a for Relapsing‐remitting Multiple Sclerosis." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing���remitting_multiple_sclerosis_Edited__no_change_to_conclusions_. Accessed 29 September 2023.
Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing���remitting_multiple_sclerosis_Edited__no_change_to_conclusions_. Accessed September 29, 2023.
Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing���remitting_multiple_sclerosis_Edited__no_change_to_conclusions_
Alemtuzumab Versus Interferon Beta 1a for Relapsing‐remitting Multiple Sclerosis [Internet]. In: Cochrane Abstracts. [cited 2023 September 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing���remitting_multiple_sclerosis_Edited__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
ID - 432006
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing���remitting_multiple_sclerosis_Edited__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
